Bend Bioscience News Today

CoreRx, Inc. today announced that it has completed its acquisition of Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and...

CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and

CoreRx set to acquire Societal CDMO in a $1.10 per share cash deal. Gain insights into this strategic move for drug formulation and manufacturing. Transaction expected to close in Q2 2024.

Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through...

Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to...

/PRNewswire/ -- Bend Bioscience, a preferred partner in drug delivery innovation, development and manufacturing, is thrilled to announce the opening of its...

Bend Bioscience will act as a research hub for pharmaceutical companies looking to outsource research. A new Bend-based bioscience lab could become op...

NovaQuest Private Equity (NQPE) has invested in Bend Bioscience, according to a news release. Bend Bioscience, based in Bend, Ore., is an early-phase contract...

/PRNewswire/ -- Bend Bioscience and QHP Capital ("QHP"), the management company for NovaQuest Private Equity ("NQPE"), have announced plans to invest in a new...